Although criteria for the diagnosis of vascular dementia (VaD) are established, the diagnostic concept is still controversial and there is no regulatory guidance for clinical drug development. Clinical trials in VaD present a number of pitfalls and challenges and, so far, no compound has received regulatory approval for this indication. The methodological issues of clinical VaD trials are discussed using the development of memantine for this indication as an example. In a pooled analysis of two placebo-controlled trials with the NMDA-antagonist memantine in VaD, the cognitive benefit by memantine treatment was more pronounced for patients with ‘small vessel disease’ than for those with other neuroradiological findings at baseline. In a subgroup of patients with ‘large vessel disease’ or macrolesions, there was less cognitive decline among the placebo patients. It may therefore be helpful to use predefined diagnostic subcategories in clinical studies in this indication. The findings further suggest that stroke or multiple infarctions may not be the primary reason for cognitive decline in VaD patients.

1.
Hachinski V, Norris JW: Vascular dementia: An obsolete concept. Commentary. Curr Opin Neurol 1994;7:3–4.
2.
Leys D, Erkinjuntti T, Desmond DW, Schmidt R, Englund E, Pasquier F, Parnetti L, Ghika J, Kalaria RN, Chabriat H, Scheltens P, Bogousslavsky J: Vascular dementia: The role of cerebral infarcts. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S38–S48.
3.
Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Demond DW: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm 2000;59(suppl):23–30.
4.
Inzitari D, Erkinjuntti T, Wallin A, Del Ser T, Romanelli M, Pantoni L: Subcortical vascular dementia as a specific target for clinical trials. Ann NY Acad Sci 2000;903:510–521.
5.
Róman GC: Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. JAMA 1987;258:1782–1788.
6.
Aguero-Torres H, Winblad B: Alzheimer’s disease and vascular dementia. Some points of confluence. Ann NY Acad Sci 2000;903:547–552.
7.
Kalaria RN, Ballard C: Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S115–S123.
8.
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS): Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–175.
9.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
10.
Ferris SH: Cognitive outcome measures. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S140–S142.
11.
Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski VC: The cognitive syndrome of vascular dementia: Implications for clinical trials. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S21–S29.
12.
Meyer JS, Rogers RL, McKlintic KJ: Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. J Am Geriatr Soc 1989;37:535–549.
13.
Herrmann WM, Stephan K, Gaede K, Apeceche M: A multicentre randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 1997;8:9–17.
14.
Bès A, Orgogozo JM, Poncet M, Rancurel G, Weber M, Bertholom N, Calvez R, Stehlé B, French Study Group of Leukoaraiosis: A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999;6:313–322.
15.
Blume J, Uhlmann KU, de la Haye R, Rettig K: Treatment of chronic cerebrovascular disease in elderly patients with pentoxifylline. J Med 1992;23:417–432.
16.
Black RS, Barclay LL, Nolan KA, Thaler HAT, Hardioman ST, Blass JP: Pentoxifylline in cerebrovascular dementia. Am Geriatr Soc 1992;40:237–244.
17.
Marcusson J, Rother M, Kittner B, Roessner M, Smith RJ, Babic T, Folnegovic-Šmalc V, Möller HJ, Labs KH: A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM-III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord 1997;8:320–328.
18.
Kittner B: Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S166–S171.
19.
Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I: Propentofylline in the treatment of Alzheimer`s disease and vascular dementia: A review of phase III trials. Dement Geriatr Cogn Disord 1998;9(suppl 1):36–43.
20.
Parnetti L, Ambrosoli L, Agliati G, Caratozzolo P, Fossati L, Frattola L, Martucci N, Murri L, Nappi G, Puca FM, Poli A, Girardello R, Senin U: Posatirelin in the treatment of vascular dementia: A double-blind multicentre study vs. placebo. Acta Neurol Scand 1996;93:456–463.
21.
Kumar V, Anand R, Messina J, Hartman R, Veach J: An efficacy and safety analysis of Exelon® in Alzheimer`s disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159–169.
22.
Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin A: Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124–134.
23.
Orgogozo JM, Forette F (for the MMM 300 Trial Group): Efficacy of memantine in mild to moderate vascular dementia (the MMM 300 Trial.) Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, April 5–8, 2000.
24.
Wilcock G (for the MMM 500 Trial Group): Cognitive improvement by memantine in a placebo-controlled trial in mild to moderate vascular dementia (the MMM 500 Trial). Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, April 5–8, 2000.
25.
Wilcock G, Stöffler A, Sahin K, Möbius HJ: Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Eur Neuropsychopharmacol 2000;10(suppl 3):S360.
26.
Zajaczkowski W, Quack G, Danysz W: Infusion of (+)-MK-801 and memantine – Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996;296:239–246.
27.
Barnes CA, Danysz W, Parsons CG: Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996;8:565–571.
28.
Möbius HJ: Pharmacological rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S172–S178.
29.
Reisberg B, Windscheif U, Ferris SH, Hingorani VN, Stöffler A, Möbius HJ: Memantine in moderately severe to severe Alzheimer’s disease: Results of a placebo-controlled 6-month trial. Neurobiol Aging 2000;21(suppl):S275.
30.
Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G: Neuroprotection and symptomatological action of memantine relevant for Alzheimer’s disease – A unified hypothesis on the mechanism of action. Neurotox Res 2000;2:85–98.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.